Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
Date:5/8/2013

ALISO VIEJO, Calif., May 8, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues of $17.4 million
  • Gross and net NUEDEXTA® sales increased to $20.8 million and $16.5 million, respectively, representing growth of 14% and 11% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $70.2 million as of March 31, 2013.
  • "Avanir achieved a major milestone with the exciting news regarding the positive CHMP opinion for NUEDEXTA in Europe. This is a significant moment in the evolution of the company towards its goal of becoming a leading mid-cap biopharmaceutical company," said Keith A. Katkin, president and CEO of Avanir.  "Additionally, we continue to execute in the U.S. as demonstrated by our commercial and clinical progress. We enter the second half of fiscal 2013 with strong momentum, a broad CNS pipeline and a continued focus on building our business."

    Fiscal 2013 Second Quarter Results

  • Total net revenues for the quarter ended March 31, 2013 were $17.4 million, compared with $10.0 million for the comparable quarter in fiscal 2012, representing 74% year-over-year growth. Total net revenues consist of NUEDEXTA net revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $30.1 million in the second quarter of fiscal 2013, compared with $25.3 million in the comparable period in fiscal 2012.
  • Cash used in operations was $9.6 million in the second quarter of fiscal 2013.
  • Net loss for the fiscal 2013 second qu
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
    2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
    3. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
    4. AVANIR Pharmaceuticals To paticipate in two conferences in March
    5. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    6. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    7. Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call
    8. Avanir Pharmaceuticals Reports Fiscal 2012 Fourth Quarter And Year-End Financial And Business Results
    9. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
    (Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
    (Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
    Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
    ... N.C., Feb. 10, 2012  Viztek, the digital radiology solution ... U-Arm at Edison Metuchen Orthopaedic Group (EMOG) in Edison, ... psychiatrist with onsite x-ray and access to an MRI facility ... EMOG performs between 65 and 85 x-ray procedures ...
    ... PRINCETON, N.J., Feb. 10, 2012 Soligenix, Inc. ... stage biopharmaceutical company, announced preliminary results today from ... time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), ... The Phase 1/2 protocol BDP-ENT-01 was ...
    Cached Medicine Technology:Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 2Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 3Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 4Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 5
    (Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
    (Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
    (Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
    (Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
    (Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
    Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2
    ... 23 (HealthDay News) -- Implantable devices designed to ... death among heart failure patients are as effective ... they are in controlled study environments, new research ... analysis of nearly 186,000 patients outfitted with either ...
    ... Richmond, Va. (Nov. 22, 2010) Researchers at Virginia ... for its involvement in tumor cell development, growth and ... chemotherapy. By inhibiting the expression of this gene, doctors ... treating aggressive cancers such as breast, liver and prostate ...
    ... Elderly adults can improve their vision with perceptual training, according ... Boston University that has implications for the health and mobility ... improved visual performance in early stages of visual processing," appears ... Vision . It was funded by a $3.5 million grant ...
    ... News) -- Increased efforts to prevent several lifestyle-related diseases ... year in medical costs, researchers say. Using 2003-2005 ... estimated how reductions in the rates of diabetes, high ... spending. The findings were released online Nov. 18 ...
    ... HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... therapy with either warfarin or a combination of Plavix ... Both therapies are prescribed for millions of Americans ... attack or stroke. But the Plavix-aspirin combination was thought ...
    ... and droplets are the primary ways influenza spreads. ... In a study published in the current issue ... ( http://www.journals.uchicago.edu/doi/abs/10.1086/656743 ), the authors examined such an ... On April 4, 2008, seven inpatients in ...
    Cached Medicine News:Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 3Health News:New function of gene in promoting cancer found by VCU researchers 2Health News:Perceptual training improves vision of the elderly 2Health News:Disease Prevention Could Save U.S. Billions of Dollars Annually 2Health News: Bleeding Risk With Plavix-Aspirin Regimen May Be Serious 2Health News: Bleeding Risk With Plavix-Aspirin Regimen May Be Serious 3
    ... with BD Xstar Blade includes a specially ... blade in prodedure and handling. The ... grind-less process for manufacturing surgical blades. ... consistency. The arch style, single-bevel geometry ...
    ... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
    Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
    An advanced microprocessor-controlled unit with superior reliability and reproducible power. Its modern electronics provides the precision and control a surgeon expects....
    Medicine Products: